Role of ERβ in clinical breast cancer

Cancer Treatment and Research

Volumn 147, Issue , 2009, Pages 17-36

  Speirs, Valerie ^a   Shaaban, Abeer M ^b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b NONE

Author keywords

Breast cancer; Estrogen receptor ; Isoforms; Tamoxifen resistance

Indexed keywords

21 (4 DIETHYLAMINOMETHYL 2 METHOXYPHENOXY) 7ALPHA METHYL 19 NORPREGNA 1,3,5(10) TRIEN 3 OL; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR BETA; ESTROGEN RECEPTOR BETA 1; ESTROGEN RECEPTOR BETA 2; ESTROGEN RECEPTOR BETA 3; ESTROGEN RECEPTOR BETA 4; ESTROGEN RECEPTOR BETA 5; TAMOXIFEN; TRILOSTANE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER GROWTH; CANCER INVASION; CANCER RISK; DRUG RESPONSE; DRUG TARGETING; EPIGENETICS; GENETIC POLYMORPHISM; HORMONE RECEPTOR INTERACTION; HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; PROTEIN VARIANT; STRUCTURE ANALYSIS; BREAST TUMOR;

BREAST NEOPLASMS; ESTROGEN RECEPTOR BETA; HUMANS;

EID: 79953770540     PISSN: 09273042     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-09463-2_2     Document Type: Article

References (111)

1. Kuiper GG, Enmark E, Pelto-Huikko M, et al. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA. 1996;93:5925-30. (Pubitemid 26190778)
2. Mosselman S, Polman J, Dijkema R. ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett. 1996;392:49-53. (Pubitemid 26268330)
3. Tremblay GB, Tremblay A, Copeland NG, et al. Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor beta. Mol Endocrinol. 1997;11:353-65. (Pubitemid 27106331)
4. Enmark E, Pelto-Huikko M, Grandien K, et al. Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab. 1997;82:4258-65. (Pubitemid 27525550)
5. Menasce LP, White GR, Harrison CJ, et al. Localization of the estrogen receptor locus (ESR) to chromosome 6q25.1 by FISH and a simple post-FISH banding technique. Genomics 1993;17:263-5. (Pubitemid 23205095)
6. Leygue E, Dotzlaw H, Watson PH, et al. Expression of estrogen receptor beta1, beta2, and beta5 messenger RNAs in human breast tissue. Cancer Res. 1999;59:1175-9. (Pubitemid 29136241)
7. Tong D, Schuster E, Seifert M, et al. Expression of estrogen receptor beta isoforms in human breast cancer tissues and cell lines. Breast Cancer Res Treat. 2002;71:249-55. (Pubitemid 34263988)
8. Iwao K, Miyoshi Y, Egawa C, et al. Quantitative analysis of estrogen receptor-beta mRNA and its variants in human breast cancers. Int J Cancer. 2000;88:733-6.
9. Poola I, Abraham J, Baldwin K, et al. Estrogen receptors beta4 and beta5 are full length functionally distinct ERbeta isoforms: cloning from human ovary and functional char-acterization. Endocrine 2005;27:227-38. (Pubitemid 41456738)
10. Chu KC, Lamar CA, Freeman HP. Racial disparities in breast carcinoma survival rates: separating factors that affect diagnosis from factors that affect treatment. Cancer 2003;97:2853-60. (Pubitemid 36605155)
11. Ogawa S, Inoue S, Watanabe T, et al. The complete primary structure of human estrogen receptor beta (hER beta) and its heterodimerization with ER alpha in vivo and in vitro. Biochem Biophys Res Commun. 1998;243:122-6. (Pubitemid 28414201)
12. Wilkinson HA, Dahllund J, Liu H, et al. Identification and characterization of a func-tionally distinct form of human estrogen receptor beta. Endocrinology 2002;143:1558-61. (Pubitemid 34274388)
13. Xu L, Pan-Hammarstrom Q, Forsti A, et al. Human estrogen receptor β 548 is not a common variant in three distinct populations. Endocrinology 2003;144:3541-6. (Pubitemid 36904433)
14. Peng B, Lu B, Leygue E, Murphy LC. Putative functional characteristics of human estrogen receptor-beta isoforms. J Mol Endocrinol. 2003;30:13-29. (Pubitemid 36305253)
15. Pike AC, Brzozowski AM, Hubbard RE, et al. Structure of the ligand-binding domain of oestrogen receptor beta in the presence ofapartial agonist and a full antagonist. EMBO J. 1999;18:4608-18. (Pubitemid 29415516)
16. Klinge CM. Estrogen receptor interactions with co-activators and co-repressors. Steroids 2000;65: 227-51. (Pubitemid 30177344)
17. Moore JT, McKee DD, Slentz-Kesler K, et al. Cloning and characterization of human estrogen receptor beta isoforms. Biochem Biophys Res Commun. 1998;247:75-8. (Pubitemid 28412528)
18. Paech K, Webb P, Kuiper GGJM, et al. Differential Ligand Activation of Estrogen Receptors ERα and ER/3 at AP1 Sites. Science 1997;277:1508-10. (Pubitemid 27449239)
19. Barkhem T, Nilsson S, Gustafsson JA. Molecular mechanisms, physiological conse-quences and pharmacological implications of estrogen receptor action. Am J Pharmaco-genomics. 2004;4:19-28. (Pubitemid 38325702)
20. Lazennec G, Bresson D, Lucas A, et al. ER beta inhibits proliferation and invasion of breast cancer cells. Endocrinology 2001;142:4120-30. (Pubitemid 32802685)
21. Murphy LC, Peng B, Lewis A, et al. Inducible upregulation of oestrogen receptor-/31 affects oestrogen and tamoxifen responsiveness in MCF7 human breast cancer cells. J Mol Endocrinol. 2005;34:553-66. (Pubitemid 40585201)
22. Paruthiyil S, Parmar H, Kerekatte V, et al. Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res. 2004;64:423-8. (Pubitemid 38114127)
23. Speirs V, Carder PJ, Lane S, et al. Oestrogen receptor β: what it means for patients with breast cancer. Lancet Oncol. 2004;5:174-81. (Pubitemid 38262850)
24. Bardin A, Boulle N, Lazennec G, et al. Loss of ERbeta expression as a common step in estrogen-dependent tumorprogression. Endocr Relat Cancer. 2004;11:537-51. (Pubitemid 39331282)
25. Ogawa S, Inoue S, Watanabe T, et al. Molecular cloning and characterization of human estrogen receptor βcx: a potential inhibitor of estrogen action in human. Nucleic Acids Res. 1998;26:3505-12. (Pubitemid 28347221)
26. Pettersson K, Delaunay F, Gustafsson JA. Estrogen receptor beta acts as a dominant regulator of estrogen signaling. Oncogene 2000;19:4970-8.
27. Chi A, Chen X, Chirala M, et al. Differential expression of estrogen receptor beta isoforms in human breast cancer tissue. Anticancer Res. 2003;23:211-6. (Pubitemid 36358520)
28. Girault I, Andrieu C, Tozlu S, et al. Altered expression pattern of alternatively spliced estrogen receptor beta transcripts in breast carcinoma. Cancer Lett. 2004;215:101-12. (Pubitemid 39221465)
29. Poola I, Abraham J, Baldwin K, et al. Estrogen receptors beta4 and beta5 are full length functionally distinct ERbeta isoforms: cloning from human ovary and functional char-acterization. Endocrine 2005;27:227-38. (Pubitemid 41456738)
30. Herynk MH, Fuqua SAW. Estrogen Receptor Mutations in Human Disease. Endocr Rev. 2004;25:869-98. (Pubitemid 39657771)
31. Poola I, Abraham J, Baldwin K. Identification often exon deleted ER[beta] mRNAs in human ovary, breast, uterus and bone tissues: alternate splicing pattern of estrogen receptor β mRNA is distinct from that of estrogen receptor a. FEBS Lett. 2002;516:133-38. (Pubitemid 34311949)
32. Poola I, Abraham J, Liu A. Estrogen receptor beta splice variant mRNAs are differen-tially altered during breast carcinogenesis. J Steroid Biochem Mol Biol. 2002;82:169-79. (Pubitemid 35435365)
33. Inoue S, Ogawa S, Horie K, et al. An Estrogen Receptor [beta] Isoform That Lacks Exon 5 Has Dominant Negative Activity on both ERα and ER/3. Biochem Biophys Res Commun. 2000;279:814-19. (Pubitemid 32042861)
34. Speirs V, Adams IP, Walton DS, et al. Identification ofWild-Type and Exon 5 Deletion Variants of Estrogen Receptor β in Normal Human Mammary Gland. J Clin Endocrinol Metab. 2000;85:1601-05. (Pubitemid 32289507)
35. Speirs V, Skliris GP, Burdall SE, et al. Distinct expression patterns of ER a and ER β in normal human mammary gland. J Clin Pathol. 2002;55:371-4. (Pubitemid 34494177)
36. Shaaban AM, O'Neill PA, Davies MP, et al. Declining estrogen receptor-beta expression defines malignant progression of human breast neoplasia. Am J Surg Pathol. 2003; 27:1502-12. (Pubitemid 37486611)
37. Shaaban AM, Speirs V. The estrogen receptors a, β, and βcx. Clin Cancer Res. 2005;11:8222;author reply 8222-3.
38. Taylor AH, Al-Azzawi F. Immunolocalisation of oestrogen receptor beta in human tissues. J Mol Endocrinol. 2000;24:145-55. (Pubitemid 30117668)
39. Saji S, Hirose M, Toi M. Clinical significance of estrogen receptor beta in breast cancer. Cancer Chemother Pharmacol. 2005;56 Suppl 1:21-6.
40. Skliris GP, Parkes AT, Limer JL, et al. Evaluation of seven oestrogen receptor β antibodies for immunohistochemistry, western blotting, and flow cytometry in human breast tissue. J Pathol. 2002;197:155-62. (Pubitemid 34567602)
41. Weitsman GE, Skliris G, Ung K, et al. Assessment ofmultiple different estrogen receptor-beta antibodies for their ability to immunoprecipitate under chromatin immunoprecipi-tation conditions. Breast Cancer Res Treat. 2006.
42. Carder PJ, Murphy C, Dervan P, et al. A Multi-Centre Investigation Towards Reaching a Consensus on the Immunohistochemical Detection of ERβ in Archival Formalin-fixed Paraffin Embedded Human Breast Tissue. Breast Cancer Res Treat. 2005; 92:287-293. (Pubitemid 41279638)
43. Iwase H, Zhang Z, Omoto Y, et al. Clinical significance of the expression of estrogen receptors alpha and beta for endocrine therapy of breast cancer. Cancer Chemother Pharmacol. 2003;52 Suppl 1:S34-8. (Pubitemid 37047022)
44. Jarvinen TA, Pelto-Huikko M, Holli K, et al. Estrogen receptor beta is coexpressed with ERalpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer. Am J Pathol. 2000;156:29-35. (Pubitemid 30644435)
45. Mann S, Laucirica R, Carlson N, et al. Estrogen receptor beta expression in invasive breast cancer. Hum Pathol. 2001;32:113-8. (Pubitemid 32150637)
46. Skliris GP, Carder PJ, Lansdown MR, et al. Immunohistochemical detection of ERbeta in breast cancer: towards more detailed receptor profiling? Br J Cancer. 2001;84:1095-8. (Pubitemid 32448508)
47. Hopp TA, Weiss HL, Parra IS, et al. Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer. Clin Cancer Res. 2004;10:7490-9. (Pubitemid 39557510)
48. Nakopoulou L, Lazaris AC, Panayotopoulou EG, et al. The favourable prognostic value of oestrogen receptor beta immunohistochemical expression in breast cancer. J Clin Pathol. 2004;57:523-8. (Pubitemid 38655949)
49. Myers E, Fleming FJ, Crotty TB, et al. Inverse relationship between ER-beta and SRC-1 predicts outcome in endocrine-resistant breast cancer. Br J Cancer. 2004;91:1687-93. (Pubitemid 39546142)
50. Omoto Y, Inoue S, Ogawa S, et al. Clinical value of the wild-type estrogen receptor beta expression in breast cancer. Cancer Lett. 2001;163:207-12. (Pubitemid 32126367)
51. Esslimani-Sahla M, Kramar A, Simony-Lafontaine J, et al. Increased estrogen receptor betacx expression during mammary carcinogenesis. Clin Cancer Res. 2005;11:3170-4. (Pubitemid 40637201)
52. Iwao K, Miyoshi Y, Egawa C, et al, Quantitative analysis of estrogen receptor-a and-β messenger RNA expression in breast carcinoma by real-time polymerase chain reaction. Cancer 2000;89:1732-38.
53. Omoto Y, Kobayashi S, Inoue S, et al. Evaluation of oestrogen receptor beta wild-type and variant protein expression, and relationship with clinicopathological factors in breast cancers. Eur J Cancer. 2002;38:380-6. (Pubitemid 34123315)
54. Park BW, Kim KS, Heo MK, et al. The changes of estrogen receptor-? variants expression in breast carcinogenesis: decrease of estrogen receptor-?2 expression is the key event in breast cancer development. J Surg. Oncol. 2006;93:504-10.
55. Murphy CE, Carder PJ, Lansdown MRJ, et al. Steroid hormone receptor expression in male breast cancer. Eur J Surg. Oncol 2006;32:44-7. (Pubitemid 43103987)
56. Roger P, Sahla ME, Makela S, et al Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res. 2001;61:2537-41. (Pubitemid 32685835)
57. Skliris GP, Munot K, Bell SM, et al. Reduced expression of oestrogen receptor beta in invasive breast cancer and its re-expression using DNA methyl transferase inhibitors in a cell line model. J Pathol. 2003;201:213-20. (Pubitemid 37258932)
58. Rody A, Diallo R, Poremba C, et al. Estrogen receptor alpha and beta, progesterone receptor, pS2 and HER-2/neu expression delineate different subgroups in ductal carci-noma in situ of the breast. Oncol Rep. 2004;12:695-9.
59. Zhao C, Lam EW, Sunters A, et al. Expression of estrogen receptor beta isoforms in normal breast epithelial cells and breast cancer: regulation by methylation. Oncogene 2003;22:7600-6. (Pubitemid 37464093)
60. Shaaban AM, Jarvis C, Moore F, et al. Prognostic significance of estrogen receptor Beta in epithelial hyperplasia ofusualtype with known outcome. Am J Surg Pathol. 2005;29:1593-9.
61. Cappelletti V, Celio L, Bajetta E, et al. Prospective evaluation of estrogen receptor-beta in predicting response to neoadjuvant antiestrogen therapy in elderly breast cancer patients. Endocr Relat Cancer. 2004;11:761-70. (Pubitemid 40065549)
62. Knowlden JM, Gee JM, Robertson JF, et al A possible divergent role for the oestrogen receptor alpha and beta subtypes in clinical breast cancer. Int J Cancer. 2000;89:209-12. (Pubitemid 30185932)
63. Davies MP, O'Neill PA, Innes H, et al. Correlation of mRNA for oestrogen receptor beta splice variants ERbeta1, ERbeta2/ERbetacx and ERbeta5 with outcome in endocrine-treated breast cancer. J Mol Endocrinol. 2004;33:773-82. (Pubitemid 40057569)
64. Murphy LC, Leygue E, Niu Y, et al Relationship of coregulator and oestrogen receptor isoform expression to de novo tamoxifen resistance in human breast cancer. Br J Cancer. 2002;87 1411-16. (Pubitemid 36044316)
65. Miller WR, Anderson TJ, Dixon JM, et al. Oestrogen receptor beta and neoadjuvant therapy with tamoxifen: prediction of response and effects of treatment. Br J Cancer. 2006;94:1333-8.
66. Saji S, Omoto Y, Shimizu C, et al. Expression of estrogen receptor (ER) (beta)cx protein in ER(alpha)-positive breast cancer: specific correlation with progesterone receptor. Cancer Res. 2002;62:4849-53. (Pubitemid 34984402)
67. Palmieri C, Lam EW, Mansi J, et al. The expression of ER beta cx in human breast cancer and the relationship to endocrine therapy and survival. Clin Cancer Res. 2004;10:2421-8. (Pubitemid 38445702)
68. Esslimani-Sahla M, Simony-Lafontaine J, Kramar A, et al. Estrogen receptor beta (ER beta) level but not its ER beta cx variant helps to predict tamoxifen resistance in breast cancer. Clin Cancer Res. 2004;10:5769-76. (Pubitemid 39180954)
69. Chang HG, Kim SJ, Chung KW, et al. Tamoxifen-resistant breast cancers show less frequent methylation of the estrogen receptor beta but not the estrogen receptor alpha gene. J Mol Med. 2005;83:132-9. (Pubitemid 40379301)
70. Murphy LC, Watson PH. Is oestrogen receptor-{beta} a predictor of endocrine therapy responsiveness in human breast cancer? Endocr Relat Cancer. 2006;13:327-334. (Pubitemid 43886661)
71. Zhao C, Gustafsson JA, Dahlman-Wright K. Functional characterization of a novel variant of estrogen receptor beta identified in screening of DNA derived from African Americans. Pharmacogenet Genomics 2006;16:379-83.
72. Zheng SL, Zheng W, Chang BL, et al. Joint effect of estrogen receptor beta sequence variants and endogenous estrogen exposure on breast cancer risk in Chinese women. Cancer Res. 2003;63:7624-9. (Pubitemid 37466685)
73. Forsti A, Zhao C, Israelsson E, et al. Polymorphisms in the estrogen receptor beta gene and risk ofbreast cancer: no association. Breast Cancer Res Treat. 2003;79:409-13. (Pubitemid 36750948)
74. Maguire P, Margolin S, Skoglund J, et al. Estrogen Receptor Beta (ESR2) Polymorph-isms in Familial and Sporadic Breast Cancer. Breast Cancer Res Treat. 2005;94:145-52. (Pubitemid 41547111)
75. Georgopoulos NA, Adonakis GL, Fotopoulos A, et al. Estrogen receptor polymorphisms in tamoxifen-treated women with breast cancer. Gynecol Endocrinol. 2006;22:185-9.
76. Hasegawa S, Miyoshi Y, Ikeda N, et al. Mutational analysis of estrogen receptor-beta gene in human breast cancers. Breast Cancer Res Treat. 2003;78:133-4. (Pubitemid 36223026)
77. Parker HD, Hanby AM, Bell SM, et al. Loss ofheterozygosity at 14q does not correlate with estrogen receptor beta negative breast cancer. Breast Cancer Res Treat. 2005;94 (suppl 1):S245.
78. Nojima D, Li LC, Dharia A, et al. CpG hypermethylation of the promoter region inactivates the estrogen receptor-/3 gene in patients with prostate carcinoma. Cancer 2001;92:2076-2083. (Pubitemid 32973317)
79. Zhao C, Lam E, W-F., et al. Expression of estrogen receptor β isoforms in normal breast epithelial cells and breast cancer: regulation by methylation. Oncogene 2003;22: 7600-06. (Pubitemid 37464093)
80. Duong V, Licznar A, Margueron R, et al. ERα and ER/3 expression and transcriptional activity are differentially regulated by HDAC inhibitors. Oncogene 2005;25:1799-06.
81. Kuiper GGJM, Carlsson B, Grandien K, et al. Comparison of the Ligand Binding Specificity and Transcript Tissue Distribution of Estrogen Receptors a and β. Endocri-nology 1997;138:863-870. (Pubitemid 27089735)
82. Kelly WK, O'Connor OA, Krug LM, et al. Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, in Patients With Advanced Cancer. J Clin Oncol. 2005;23:3923-31. (Pubitemid 46218695)
83. Kelloff GJ, Lippman SM, Dannenberg AJ, et al. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer-a plan to move forward. Clin Cancer Res. 2006.
84. Jordan V. Designer estrogens. Sci Am. 1998;279:60-7.
85. Yamamoto Y, Shibata J, Yonekura K, et al. TAS-108, a novel oral steroidal antiestro-genic agent, is a pure antagonist on estrogen receptor alpha and a partial agonist on estrogen receptor beta with low uterotrophic effect. Clin Cancer Res. 2005;11:315-22. (Pubitemid 40075810)
86. Schopfer U, Schoeffter P, Bischoff SF, et al. Toward selective ERbeta agonists for central nervous system disorders: synthesis and characterization ofaryl benzthiophenes. J Med Chem. 2002;45:1399-401. (Pubitemid 34246102)
87. Malamas MS, Manas ES, McDevitt RE, et al. Design and synthesis ofaryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004;47:5021-40. (Pubitemid 39314900)
88. De Angelis M, Stossi F, Carlson KA, et al. Indazole estrogens: highly selective ligands for the estrogen receptor beta. J Med Chem. 2005;48:1132-44. (Pubitemid 40270455)
89. Guerini V, Sau D, Scaccianoce E, et al. The androgen derivative 5alpha-androstane-3beta,17beta-diol inhibits prostate cancer cell migration through activation of the estrogen receptor beta subtype. Cancer Res. 2005;65:5445-53. (Pubitemid 40827358)
90. Puddefoot JR, Barker S, Glover HR, et al. Non-competitive steroid inhibition ofoestro-gen receptor functions. Int J Cancer. 2002;101:17-22. (Pubitemid 34832992)
91. De Angelis M, Stossi F, Waibel M, et al. Isocoumarins as estrogen receptor beta selective ligands: isomers of isoflavone phytoestrogens and their metabolites. Bioorg Med Chem. 2005;13:6529-42. (Pubitemid 41539317)
92. Omoto Y, Eguchi H, Yamamoto-Yamaguchi Y et al. Estrogen receptor (ER) beta1 and ERbetacx/beta2 inhibit ERalpha function differently in breast cancer cell line MCF7. Oncogene. 2003;22:5011-20. (Pubitemid 37028337)
93. Fuqua SAW, Schiff R, Parra I, et al. Estrogen receptor β protein in human breast cancer: correlation with clinical tumour parameters. Cancer Res. 2003;63: 2343-439.
94. Koda M, Sulkowski S, Kanczuga-Koda L, et al. Expression of ERalpha, ERbeta and Ki-67 in primary tumors and lymph node metastases in breast cancer. Oncol Rep. 2004;11: 753-59.
95. Stefanou D, Batistatou A, Briasoulis E et al. Estrogen receptor beta (ERbeta) expression in breast carcinomas is not correlated with estrogen receptor alpha (ERalpha) and prognosis: the Greek experience. Eur J Gynaecol Oncol. 2004;25:457-61. (Pubitemid 38954523)
96. Jensen EV, Cheng G, Palmieri C et al. Estrogen receptors and proliferation markers in primary and recurrent breast cancer. Proc Natl Acad Sci USA. 2001;98: 15197-02.
97. Jarzabek K, Koda M, Kozloski L et al. Distinct mRNA, protein expression patterns and distribution of oestrogen receptors alpha and beta in human primary breast cancer: correlation with proliferation marker Ki-67 and clinicopathological factors. Eur J Cancer. 2005;41:2924-94.
98. Miyoshi Y, Taguchi T, Gustafsson JA, et al. Clinicopathological characteristics of estrogen receptor-beta-positive human breast cancers. Jpn J Cancer Res. 2001;92: 1057-61. (Pubitemid 33048784)
99. Papadaki I, Mylona E, Giannopouloui I, et al. PPARgamma expression in breast cancer: clinical value and correlation with ERbeta. Histopathology. 2005;46: 37-42. (Pubitemid 40193696)
100. O'Neill PA, Davies MP, Shaaban AM et al. Wild-type oestrogen receptor beta (ERbeta1) mRNA and protein expression in Tamoxifen-treated post-menopausal breast cancers. Br J Cancer. 2004;91:1694-102.
101. Fleming FJ, Hill AD, McDermott EW et al. Differential recruitment of coregulator proteins steroid receptor coactivator-1 and silencing mediator for retinoid and thyroid receptors to the estrogen receptor-estrogen response element by beta-estradiol and 4-hydroxytamoxifen in human breast cancer. J Clin Endocrinol Metab. 2004;89: 375-83. (Pubitemid 38183907)
102. Saunders PT, Millar MR, Williams K et al. Expression of oestrogen receptor beta (ERbeta1) protein in human breast cancer biopsies. Br J Cancer. 2002;86: 250-56. (Pubitemid 34185154)
103. Choi Y, Pinto M. Estrogen receptor beta in breast cancer: associations between ERbeta, hormonal receptors, and other prognostic biomarkers. Appl Immunohistochem Mol Morphol. 2005;13:19-24. (Pubitemid 40283798)
104. Gruvberger-Saal SK, Bendahl PO, Saal LH et al. Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma. Clin Cancer Res. 2007; 13: 1987-1994. (Pubitemid 46649864)
105. Novelli F, Milella M, Melucci E et al. A divergent role for estrogen receptor beta in node-positive and node-negative breast cancer classified according to molecular sub-types: an observational prospective study. Breast Cancer Res. 2008; 10: R74.
106. Vinayagam R, Sibson DR, Holcombe C, et al. Association of oestrogen receptor beta 2 (ER beta 2/ER beta cx) with outcome of adjuvant endocrine treatment for primary breast cancer-a retrospective study. BMC Cancer. 2007; 7: 131-140.
107. Sugiura H, Toyama T, Hara Y et al. Expression of estrogen receptor beta wild-type and its variant ERbetacx/beta2 is correlated with better prognosis in breast cancer. Jpn J Clin Oncol. 2007; 37: 820-828. (Pubitemid 350259000)
108. Skliris GP, Leygue E, Curtis-Snell L et al. Expression of oestrogen receptor-beta in oestrogen receptor-alpha negative human breast tumours. Br J Cancer. 2006; 95: 616-626. (Pubitemid 44325902)
109. Honma N, Horii R, Iwase T, et al. Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. J Clin Oncol. 2008; 26:3727-3734.
110. Shaaban AM, Green AR, Karthik S et al. Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients. Clin Cancer Res. 2008; 14: 5228-5235.
111. Skliris GP, Leygue E, Watson PH et al. Estrogen receptor alpha negative breast cancer patients: estrogen receptor beta as a therapeutic target. J Steroid Biochem Mol Biol. 2008; 109: 1-10.